Cencora shares show bullish momentum after a Q3 earnings beat, though the stock continues to trail peer Cardinal Health's 60% annual gain.
The Dow Jones Industrial Average is used as a benchmark to compare Cencora's performance over different timeframes.
Cencora has shown mixed performance, lagging behind the Dow Jones Industrial Average with a 9% gain over the past 52 weeks compared to the index's 16% rise. Despite this long-term underperformance, the stock has recently gained momentum, rising 18.5% in the last three months and trading above its 50-day and 200-day moving averages following a positive Q3 2026 earnings report where adjusted EPS of $4.48 beat analyst forecasts.
The consensus rating among 15 analysts is a 'Strong Buy' with a mean price target of $366.50.
Cencora reported Q3 2026 revenue of $84.8 billion (a miss) but achieved an adjusted EPS of $4.48, which topped Wall Street forecasts.
Cardinal Health is highlighted as a primary industry peer that has significantly outperformed Cencora over the past year. While Cencora struggled to keep pace with broader market indices, Cardinal Health demonstrated strong relative strength with a 60% growth rate during the same 52-week period.
Cardinal Health has significantly outperformed Cencora, achieving 60% growth over the past year compared to Cencora's 9% gain.
Cencora, Inc. (COR) shows strong short-term momentum, climbing 18.5% over the last three months following a Q3 earnings beat. While the stock currently trades above its 50-day and 200-day moving averages, it remains down 14% from its 52-week high and has underperformed the Dow Jones Industrial Average over the past year.
While Cencora has outperformed the Dow Jones Industrial Average by 18.5% over the last three months, it has lagged behind the index's 16% annual gain with a 9% increase over the past 52 weeks.